Pioneering novel treatment paradigms for immune-mediated and inflammatory conditions

MC2 Therapeutics is a commercial biotech company developing novel treatment paradigms for immunology and inflammation (“I&I”) diseases for which there are no or very limited approved treatment options).

By combining our cross-silo thinking and deep knowledge of immunology with a multi-disciplinary approach spanning all fields of science and product development we have an enhanced ability to identify new treatment opportunities that are truly differentiated and advance them through clinical development to patients globally.

We have moved two first-in-class drug candidates with novel modes of action and multiple indication potential (“I&I pipeline in a product”) into phase 2 development. These are:

MC2-32: Oral HSP90 Inhibitor with a unique specific tissue targeting profile modulating multiple pro-inflammatory pathways and relevant immune responses with a uniquely favorable safety profile.

MC2-25: Iso-cyanate Scavenger addressing non-enzymatic posttranslational protein and amino acid modification (carbamylation) in the skin by iso-cyanate, a dissociation product of urea.

We are currently pursuing multiple indications where there are no or very limited approved treatment options including MC2-32 for Hidradenitis Suppurativa (Ph2a completed) and MC2-25 for Vulvar Lichen Sclerosus (Ph2a ongoing).

Our operational excellence integrates the commercial experience and knowledge gained from bringing our first approved drug Wynzora® Cream for plaque psoriasis to market in the US and Europe as part of our global partnering strategy for Wynzora®.

Our highly experienced team and global network of KOLs combined with our experience in product development and commercialization, gives us the in-depth knowledge to take our novel first-in-class drug candidates through clinical development and to the patients that need them most.

Read more about our pipeline here.

Read more about Wynzora® Cream drug for treatment of plaque psoriasis in adults here.


We are committed to pioneering novel treatment paradigms for immune-mediated and inflammatory diseases and to redefine the treatment experience for patients.

Read more about our platform, pipeline and purpose in our corporate presentation.